Compare Tango Therapeutics Inc. (TNGX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Exxon Mobil Corporation — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Exxon Mobil Corporation trades at $177.65 (market cap $715.80B). The key difference: Exxon Mobil Corporation is far larger — about 190.9× Tango Therapeutics Inc.'s market cap, and Exxon Mobil Corporation pays a 2.37% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Exxon Mobil Corporation for 100 Days on average.
| TNGX | XOM | |
|---|---|---|
Market Cap | $3.75B | $715.80B |
Volume | 9,619,106 | 11,362,664 |
Sector | Health | Energy |
52-Week High | $32.90 | $177.06 |
52-Week Low | $7.50 | $110.64 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $2.77B | $747.58B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
ExxonMobil (XOM) trades at $172.15, up 1.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $323.91B in 2025 (SEC filing, 2025), though net income margin remains solid at 9.07%. Recent news highlights potential expansion into Venezuela's oil fields (Reuters, 2026-09-16) and operational updates in Guyana and Angola, supporting long-term growth targets.
The stock offers value with a P/E of 22.4 and strong cash flow, but faces headwinds from volatile oil prices and execution risks in new ventures. Analyst consensus is mixed with a $166.67 price target (MarketBeat, 2026-09-17), suggesting cautious optimism amid geopolitical and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
